| Autor: |
Tokutomi T; Iwate Tohoku Medical Megabank Organization, Iwate Medical University, Shiwa 020-3694, Japan.; Department of Clinical Genetics, School of Medicine, Iwate Medical University, Iwate 020-8505, Japan., Yoshida A; Iwate Tohoku Medical Megabank Organization, Iwate Medical University, Shiwa 020-3694, Japan.; Department of Clinical Genetics, School of Medicine, Iwate Medical University, Iwate 020-8505, Japan., Fukushima A; Iwate Tohoku Medical Megabank Organization, Iwate Medical University, Shiwa 020-3694, Japan.; Department of Clinical Genetics, School of Medicine, Iwate Medical University, Iwate 020-8505, Japan., Nagami F; Tohoku Medical Megabank Organization, Tohoku University, Sendai 980-0872, Japan., Minoura Y; Departments of Medical Genetics and Genomics, School of Medicine, Sapporo Medical University, Sapporo 060-8556, Japan., Sasaki M; Iwate Tohoku Medical Megabank Organization, Iwate Medical University, Shiwa 020-3694, Japan. |
| Abstrakt: |
Genome-wide association studies have been employed to develop numerous risk prediction models using polygenic risk scores (PRSs) for multifactorial diseases. However, healthcare providers lack confidence in their understanding of PRS risk stratification for multifactorial diseases, which underscores the need to assess the readiness of PRSs for clinical use. To address this issue, we surveyed the perceptions of healthcare providers as stakeholders in the clinical implementation of genetic-based risk prediction for multifactorial diseases. We conducted a web-based study on the need for risk prediction based on genetic information and the appropriate timing of testing for 12 multifactorial diseases. Responses were obtained from 506 stakeholders. Positive perceptions of genetic risk testing were found for adult-onset chronic diseases. As per participant opinion, testing for adult-onset diseases should be performed after the age of 20 years, whereas testing for psychiatric and allergic disorders that manifest during childhood should be performed from birth to 19 years of age. The stakeholders recognized the need for genetic risk testing for diseases that develop in adulthood, believing that the appropriate testing time is after maturity. This study contributes to the discussion on the clinical implementation of the PRS for genetic risk prediction of multifactorial diseases. |
